source
- MimiVax's glioblastoma vaccine falls short of Phase 2b primary endpointMimiVax reported that its investigational vaccine for glioblastoma did not achieve the primary efficacy goal in a Phase 2b trial. The study, more than a decade in development, compared the vaccine…
- AbbVie/Genmab’s Epkinly halves progression risk in frontline DLBCL trialA Phase 3 study of the bispecific antibody Epkinly combined with standard chemotherapy showed nearly a 50% reduction in the risk of disease progression or death compared with chemotherapy alone in…